Peter Klare Selected Research

exemestane (Aromasin)

4/2020

Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Klare Research Topics

Disease

12	Breast Neoplasms (Breast Cancer) 01/2022 - 08/2007
7	Ovarian Neoplasms (Ovarian Cancer) 01/2017 - 02/2008
5	Triple Negative Breast Neoplasms 01/2022 - 06/2014
5	Neoplasms (Cancer) 10/2021 - 07/2008
3	Adenoma (Adenomas) 01/2020 - 02/2015
3	Carcinoma (Carcinomatosis) 10/2017 - 08/2012
3	Thrombocytopenia (Thrombopenia) 01/2017 - 08/2008
3	Neutropenia 01/2015 - 08/2008
2	Polyps 03/2019 - 01/2018
2	Hypoxia (Hypoxemia) 01/2016 - 12/2015
2	Nausea 11/2015 - 08/2008
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020
1	Neoplasm Metastasis (Metastasis) 10/2019
1	Abdominal Pain (Pain, Abdominal) 01/2017
1	Leukopenia 01/2017
1	Ascites 01/2017
1	Apnea 01/2016
1	Hypotension (Low Blood Pressure) 12/2015
1	Pathologic Complete Response 03/2015
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2015
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2015
1	Febrile Neutropenia 01/2015
1	Alopecia (Baldness) 08/2008
1	Vomiting 08/2008
1	Ovarian Epithelial Carcinoma 03/2008
1	Body Weight (Weight, Body) 08/2007

Drug/Important Bio-Agent (IBA)

7	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 02/2008
7	taxaneIBA 01/2021 - 08/2007
6	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 02/2008
5	AnthracyclinesIBA 01/2021 - 08/2007
4	PlatinumIBA 06/2014 - 03/2008
3	liposomal doxorubicin (Doxil)FDA Link 01/2022 - 03/2008
3	Propofol (Diprivan)FDA LinkGeneric 01/2020 - 12/2015
3	human ERBB2 proteinIBA 10/2017 - 08/2007
3	treosulfanIBA 01/2017 - 08/2012
2	Epirubicin (Ellence)FDA LinkGeneric 01/2022 - 01/2019
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022 - 01/2019
2	ErbB Receptors (EGF Receptor)IBA 10/2021 - 03/2015
2	Bevacizumab (Avastin)FDA Link 04/2020 - 06/2014
2	Capecitabine (Xeloda)FDA Link 04/2020 - 08/2007
2	Pharmaceutical PreparationsIBA 01/2020 - 01/2017
2	Phenobarbital (Luminal)FDA Link 10/2019 - 10/2017
2	Alkylating AgentsIBA 12/2015 - 08/2012
2	Trastuzumab (Herceptin)FDA Link 06/2014 - 08/2007
2	Topotecan (Hycamtin)FDA LinkGeneric 08/2008 - 07/2008
1	Hormones (Hormone)IBA 10/2021
1	Everolimus FDA Link 04/2020
1	exemestane (Aromasin)FDA Link 04/2020
1	Cell-Free Nucleic AcidsIBA 01/2020
1	SolutionsIBA 03/2019
1	Acetic Acid (Vinegar)FDA LinkGeneric 03/2019
1	Coloring Agents (Dyes)IBA 01/2018
1	cabazitaxel FDA Link 10/2017
1	Formaldehyde (Formol)FDA Link 10/2016
1	ParaffinIBA 10/2016
1	Midazolam (Versed)FDA LinkGeneric 01/2016
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 11/2015
1	Messenger RNA (mRNA)IBA 03/2015
1	Indicators and Reagents (Reagents)IBA 02/2015
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2015
1	pegfilgrastim (Neulasta)FDA Link 01/2015
1	SaltsIBA 06/2014
1	Gemcitabine FDA Link 07/2008
1	Etoposide (VP 16)FDA LinkGeneric 07/2008
1	Cytotoxins (Cytolysins)IBA 03/2008
1	1-dodecylpyridoxal (PLD)IBA 03/2008
1	dimemorfan (AT 17)IBA 02/2008
1	Monoclonal AntibodiesIBA 08/2007
1	CarbamatesIBA 08/2007
1	Taxoids (Taxanes)IBA 08/2007

Therapy/Procedure

9	Neoadjuvant Therapy 01/2022 - 06/2014
7	Drug Therapy (Chemotherapy) 10/2021 - 07/2008
5	Therapeutics 04/2020 - 03/2008
1	Surgical Instruments (Clip) 01/2015
1	Treatment Delay 08/2008